GSK grabs an option to Five Prime therapies; Annalisa Jenkins tapped as new CEO of Dimension Therapeutics; AstraZeneca opens a big new IT center in India;

@FierceBiotech: Lilly takes the lead on AstraZeneca's Alzheimer's drug in $500M deal. News | Follow @FierceBiotech

@JohnCFierce: Biotech R&D is changing. Don't get left behind. (A shameless plug for upcoming executive breakfast panel in Boston). More | Follow @JohnCFierce

@DamianFierce: Oxygen Bio will soon be Tenax Therapeutics. Release | Follow @DamianFierce

@EmilyMFierce: Great piece on the trials and tribulations of stem cell research. Report from the NYT | Follow @EmilyMFierce

> GlaxoSmithKline ($GSK) has taken an option on the muscle disease drugs developed at South San Francisco-based Five Prime. The deal dates back 4 years. Five Prime gets a payment of $1.5 million in connection with the option exercise and up to $122.5 million in preclinical, development and commercial-related milestone payments and royalties in the low- to mid-single-digit range on net sales of products related to the target. Release

> Cambridge, MA-based Dimension Therapeutics, a gene therapy upstart, named Annalisa Jenkins as its new CEO. Jenkins recently wrapped a stint as head of R&D at Merck KGaA and earlier worked for Bristol-Myers Squibb ($BMY). Release

> AstraZeneca ($AZN) has opened up a new Global Technology Centre to build up its IT infrastructure. The center plans to have a staff of 300 by the end of this year. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Danaher cements commitment to dental with $2.2B Nobel acquisition. Article | Follow @FierceMedDev

@MichaelGFierce:  Liposome research adds up to better #cancer treatment options. More | Follow @MichaelGFierce

> WSJ: What are the costs and benefits of early cancer screening? Item

> Harvard researchers develop dialysis device to fight Ebola. Story

> Former Alere execs assemble $3.8B take-private offer. Report

Pharma News

@FiercePharma: Top-read in FierceAnimalHealth Mon: FDA seeks input on conditional approvals for new animal health products. Story | Follow @FiercePharma

@EricPFierce: Merck KGaA turns to India's Lupin to manufacture $2B worth of drugs in emerging markets. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Would Ian Read keep his AZ deal promises? U.K. panel eyes new rules to enforce them. ICYMI yesterday | Follow @CarlyHFierce

> Switzerland wants to slash drug prices? Not so fast, say Novartis and Roche. More

> Allergan, Valeant agree on meeting date. Now, the fight for shareholder votes. Story

> NY sues Actavis and Forest for 'monopoly' on Alzheimer's drug. Report

Biotech Research News

> Notable academic-pharma alliances of 2014. Feature

> Geneva Foundation gets $3M NIH grant for Ebola drug work. News

> Protein stops bone loss in arthritic mice. More

> Google's Calico acquires UT Southwestern compounds for neurodegenerative disorders. Story

> $64M NIH initiative will catalog cell responses to drugs. Article

Pharma Manufacturing News

> Gilead hands Sovaldi manufacturing tech to 7 generics makers. Report

> Merck negotiates huge production deal with Lupin. More

> Hikma opens oncology API plant in Jordan. Article

> India's top drugmakers forecast to invest $8B in production upgrades. Item

> Hospira again reports a human hair discovered in a product. Story

Suggested Articles

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…

J&J plans to have a vaccine in the clinic by September and win emergency use authorization early next year.

The biotech is pausing enrollment in some infectious and rare disease trials while continuing to try to add patients to its cancer studies.